Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. They utilize their proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to identify patients most likely to benefit from their drug candidates. The company's lead candidate, ACR-368, is a selective inhibitor of the DNA Damage Response (DDR) checkpoint kinases, CHK1 and CHK2, demonstrating clinical activity in a range of solid tumors.

Acrivon's approach is to match their therapies to patients whose tumors are predicted to be sensitive, achieving patient responder enrichment and increasing the likelihood of successful clinical development. They believe their unique proteomics-based approach can effectively predict drug response and overcome the limitations of traditional genomics-based methods.

Acrivon Therapeutics is a clinical-stage oncology company dedicated to developing targeted therapies that improve the lives of cancer patients. They leverage their proprietary precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to create OncoSignature companion diagnostics that identify patients who will benefit most from their drug candidates. By accurately matching therapies with the right patients, Acrivon aims to accelerate precision oncology drug development and deliver real therapeutic outcomes.

Acrivon Therapeutics promotes a culture of scientific excellence, passion, and teamwork. They value diversity and integrity, while encouraging their employees to realize their full potential in both their professional and personal lives. The company fosters a collaborative environment characterized by openness, creativity, and a positive "can-do" attitude.

Acrivon Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace, recognizing that a variety of perspectives and backgrounds enrich innovation and patient care. They value diversity, integrity, and passion for scientific excellence, and care deeply about their patients. This commitment translates to creating an environment that encourages open communication, creativity, fresh perspectives, and a positive can-do attitude, where team members are challenged to realize their full potential.